K. Ohno

发表

Computational Insights into Binding of Bisphosphates to Farnesyl Pyrophosphate Synthase

K. Mori, K. Ohno, M. Orita, 2011, Current medicinal chemistry.

Prediction of the clinical phenotype of Fabry disease based on protein sequential and structural information

Jun Sese, Seiji Saito, Hitoshi Sakuraba, 2010, Journal of Human Genetics.

Advances in fragment-based drug discovery platforms

Masaya Orita, Yasushi Amano, Tatsuya Niimi, 2009, Expert opinion on drug discovery.

Lead generation and examples opinion regarding how to follow up hits.

Masaya Orita, Tatsuya Niimi, K. Ohno, 2011, Methods in enzymology.

Fabry disease in a Japanese population-molecular and biochemical characteristics

K. Ohno, H. Sakuraba, T. Togawa, 2018, Molecular genetics and metabolism reports.

Structural bases of GM1 gangliosidosis and Morquio B disease

K. Ikeda, Mizuki Morita, K. Ohno, 2009, Journal of Human Genetics.

Endogenous S-sulfhydration of PTEN helps protect against modification by nitric oxide.

T. Uehara, K. Ohno, K. Okuda, 2015, Biochemical and biophysical research communications.

Unique "delta lock" structure of telmisartan is involved in its strongest binding affinity to angiotensin II type 1 receptor.

R. Morishita, I. Komuro, J. Higaki, 2011, Biochemical and biophysical research communications.

Molecular modeling of vasopressin receptor and in silico screening of V1b receptor antagonists

Y. Fukunishi, Haruki Nakamura, Yohsuke Hagiwara, 2013, Expert opinion on drug discovery.

Docking study and binding free energy calculation of poly (ADP-ribose) polymerase inhibitors

K. Ohno, M. Orita, H. Fujitani, 2011, Journal of molecular modeling.

Large-Scale Computing for Protein-Protein Binding Free Energy Calculation

Yoichi Muraoka, Sayaka Akioka, Tamotsu Noguchi, 2008, PDPTA.

Discovering a hidden binding site of spermidine synthase inhibitors for Chagas disease by combining molecular simulations and X-ray crystallography

T. Ishida, Y. Akiyama, M. Sekijima, 2021 .

Molecular mechanism for stabilization of a mutant α-galactosidase A involving M51I amino acid substitution by imino sugars.

Y. Chiba, K. Ohno, H. Sakuraba, 2011, Molecular genetics and metabolism.

Structural modeling of mutant α-glucosidases resulting in a processing/transport defect in Pompe disease

M. Sekijima, M. Kroos, K. Ohno, 2009, Journal of Human Genetics.

In silico, in vitro, X-ray crystallography, and integrated strategies for discovering spermidine synthase inhibitors for Chagas disease

T. Ishida, Y. Akiyama, M. Sekijima, 2017, Scientific Reports.

Structural characterization of mutant α-galactosidases causing Fabry disease

K. Ohno, H. Sakuraba, S. Saito, 2008, Journal of Human Genetics.

Structural study on mutant α-L-iduronidases: insight into mucopolysaccharidosis type I

T. Okuyama, K. Ohno, H. Sakuraba, 2008, Journal of Human Genetics.

Synthesis, biological evaluation, and metabolic stability of acrylamide derivatives as novel CCR3 antagonists.

K. Ohno, M. Takeuchi, Keiko Suzuki, 2009, Bioorganic & medicinal chemistry.

Therapeutic Potential of Intracerebroventricular Replacement of Modified Human β-Hexosaminidase B for GM2 Gangliosidosis

D. Tsuji, K. Ohno, H. Sakuraba, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Comparative Study of Structural Changes Caused by Different Substitutions at the Same Residue on α-Galactosidase A

K. Ohno, H. Sakuraba, S. Saito, 2013, PloS one.

Fabry-database.org: database of the clinical phenotypes, genotypes and mutant α-galactosidase A structures in Fabry disease

K. Ohno, H. Sakuraba, S. Saito, 2011, Journal of Human Genetics.

Mutant α-galactosidase A with M296I does not cause elevation of the plasma globotriaosylsphingosine level.

K. Ohno, H. Sakuraba, K. Doi, 2012, Molecular genetics and metabolism.

Structural basis for telmisartan-mediated partial activation of PPAR gamma

K. Ohno, M. Orita, M. Takeuchi, 2012, Hypertension Research.

Identification, synthesis, and biological evaluation of 6-[(6R)-2-(4-fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3(2H)-one (AS1940477), a potent p38 MAP kinase inhibitor.

H. Yamazaki, K. Ohno, M. Takeuchi, 2012, Journal of medicinal chemistry.

Are There Differences between Launched Drugs, Clinical Candidates, and Commercially Available Compounds?

Yuichi Nagahara, Kazuki Ohno, Masaya Orita, 2010, J. Chem. Inf. Model..

Agreement of drug discovery data with Benford's law

Yosuke Hagiwara, Kazuki Ohno, Masaya Orita, 2013, Expert opinion on drug discovery.

Use of Benford's law in drug discovery data.

Kazuki Ohno, Masaya Orita, Ayako Moritomo, 2010, Drug discovery today.

Chaperone therapy for Krabbe disease: potential for late-onset GALC mutations

Yoshiyuki Suzuki, K. Higaki, E. Nanba, 2015, Journal of Human Genetics.

Late-onset Krabbe disease is predominant in Japan and its mutant precursor protein undergoes more effective processing than the infantile-onset form.

K. Ozono, K. Ohno, H. Sakuraba, 2014, Gene.

Structural basis of aspartylglucosaminuria.

K. Ohno, H. Sakuraba, Toshihiro Suzuki, 2008, Biochemical and biophysical research communications.

Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease.

T. Kanekura, Y. Jigami, Y. Chiba, 2009, American journal of human genetics.

Fabry disease: biochemical, pathological and structural studies of the α-galactosidase A with E66Q amino acid substitution.

T. Kanekura, H. Yoo, A. Satomura, 2012, Molecular genetics and metabolism.

Plasma mutant α-galactosidase A protein and globotriaosylsphingosine level in Fabry disease

F. Shibasaki, K. Ohno, H. Sakuraba, 2014, Molecular genetics and metabolism reports.

Molecular diagnosis of 65 families with mucopolysaccharidosis type II (Hunter syndrome) characterized by 16 novel mutations in the IDS gene: Genetic, pathological, and structural studies on iduronate-2-sulfatase.

T. Okuyama, M. Kosuga, K. Ohno, 2016, Molecular genetics and metabolism.

Structural consequences of amino acid substitutions causing Tay-Sachs disease.

K. Ohno, H. Sakuraba, S. Saito, 2008, Molecular genetics and metabolism.

Structural bases of Wolman disease and cholesteryl ester storage disease.

K. Ohno, H. Sakuraba, Toshihiro Suzuki, 2012, Molecular genetics and metabolism.

On–off system for PI3-kinase–Akt signaling through S-nitrosylation of phosphatase with sequence homology to tensin (PTEN)

S. Lipton, H. Hara, T. Uehara, 2011, Proceedings of the National Academy of Sciences.

Structural Basis of Mucopolysaccharidosis Type II and Construction of a Database of Mutant Iduronate 2-Sulfatases

T. Okuyama, K. Ohno, H. Sakuraba, 2016, PloS one.

Human α-l-iduronidase uses its own N-glycan as a substrate-binding and catalytic module

Seiji Saito, Hitoshi Sakuraba, H. Taniguchi, 2013, Proceedings of the National Academy of Sciences.

Structural and clinical implications of amino acid substitutions in α-L-iduronidase: insight into the basis of mucopolysaccharidosis type I.

K. Ohno, H. Sakuraba, S. Saito, 2014, Molecular genetics and metabolism.

In silico, in vitro, X-ray crystallography, and integrated strategies for discovering spermidine synthase inhibitors for Chagas disease

T. Ishida, Y. Akiyama, M. Sekijima, 2017, Scientific Reports.

Pharmacophore Modeling for Anti-Chagas Drug Design Using the Fragment Molecular Orbital Method

M. Sekijima, T. Honma, Yohsuke Hagiwara, 2015, PloS one.

Novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potent and orally active STAT6 inhibitors.

S. Kuromitsu, K. Ohno, M. Orita, 2009, Bioorganic & medicinal chemistry.

Molecular interaction of imino sugars with human alpha-galactosidase: Insight into the mechanism of complex formation and pharmacological chaperone action in Fabry disease.

Toshihide Kobayashi, K. Ohno, H. Sakuraba, 2009, Molecular genetics and metabolism.

Biochemical and structural study on a S529V mutant acid α-glucosidase responsive to pharmacological chaperones

S. Tsujino, K. Ohno, H. Sakuraba, 2011, Journal of Human Genetics.

Binding parameters and thermodynamics of the interaction of imino sugars with a recombinant human acid alpha-glucosidase (alglucosidase alfa): insight into the complex formation mechanism.

M. Ikekita, Toshihide Kobayashi, D. Tsuji, 2008, Clinica chimica acta; international journal of clinical chemistry.

Structural and clinical implications of amino acid substitutions in N-acetylgalactosamine-4-sulfatase: insight into mucopolysaccharidosis type VI.

K. Ohno, H. Sakuraba, S. Saito, 2008, Molecular genetics and metabolism.

Small-World Phenomena in Chemical Library Networks: Application to Fragment-Based Drug Discovery

Naoki Tanaka, Kazuki Ohno, Masaya Orita, 2009, J. Chem. Inf. Model..

Two 'Golden Ratio' indices in fragment-based drug discovery.

Kazuki Ohno, Masaya Orita, Tatsuya Niimi, 2009, Drug discovery today.

Structural basis of neuronal ceroid lipofuscinosis 1

K. Ohno, H. Sakuraba, Toshihiro Suzuki, 2010, Brain and Development.

In Silico Fragment Screening by Replica Generation (FSRG) Method for Fragment-Based Drug Design

Haruki Nakamura, Yoshifumi Fukunishi, Kazuki Ohno, 2009, J. Chem. Inf. Model..

A heterozygous female with Fabry disease due to a novel α-galactosidase A mutation exhibits a unique synaptopodin distribution in vacuolated podocytes.

K. Ohno, H. Sakuraba, H. Naiki, 2015, Clinical Nephrology.

Advances in fragment-based drug discovery platforms

K. Ohno, M. Orita, Masaichi Warizaya, 2009, Expert opinion on drug discovery.

Database of the clinical phenotypes, genotypes and mutant arylsulfatase B structures in mucopolysaccharidosis type VI

M. Sekijima, K. Ohno, H. Sakuraba, 2012, Journal of Human Genetics.

Small-World Phenomena in Chemical Library Networks: Application to Fragment-Based Drug Discovery

K. Mori, K. Ohno, M. Orita, 2009, J. Chem. Inf. Model..

Discovery of a Hidden Trypanosoma cruzi Spermidine Synthase Binding Site and Inhibitors through In Silico, In Vitro, and X-ray Crystallography

T. Ishida, Y. Akiyama, M. Sekijima, 2023, ACS omega.